Endocrinology | Home | MIMS Malaysia

Malaysia
Search
Sign In

Endocrinology Search

Endocrinology

Endocrinology

Home News Diseases Conferences Special Reports Multimedia

VERTIS SU: Ertugliflozin noninferior to glimepiride in reducing HbA1c, at cost of genital infection

Pearl Toh, 7 hours ago

Ertugliflozin 15 mg once daily is noninferior to the sulphonylurea glimepiride in HbA1c reduction over 52 weeks in patients with type 2 diabetes (T2D) who are inadequately controlled on metformin, according to the VERTIS SU* trial presented at the EASD 2017 in Lisbon, Portugal.

Semaglutide + standard of care encourages weight loss in patients with T2D and high CV risk

Roshini Claire Anthony, Yesterday

The addition of the glucagon-like peptide-1 analogue semaglutide to standard of care resulted in sustained reduction in weight and waist circumference in individuals with type 2 diabetes (T2D) with high cardiovascular risk, according to the phase III SUSTAIN 6* trial presented at EASD 2017.

Nasal glucagon a desirable needle-free alternative for hypoglycaemia treatment in children

Jairia Dela Cruz, Yesterday

Intranasal delivery of dry powder glucagon in paediatric type 1 diabetes (T1D) patients with moderate to severe hypoglycaemia appears to induce recovery over half an hour, with the rise in blood glucose occurring within 15 minutes, according to a study presented at the 53rd Annual Meeting of the European Association for the Study of Diabetes (EASD 2017).

inTANDEM3 demonstrates potential of sotagliflozin in T1D

Roshini Claire Anthony, 2 days ago

The addition of the sodium-glucose cotransporters 1 and 2 (SGLT1 and SGLT2) inhibitor sotagliflozin improved glycated haemoglobin levels, systolic blood pressure, and weight in patients with type 1 diabetes (T1D) on insulin therapy, according to findings of the InTandem3* trial presented at EASD 2017.

CGM adoption reduces frequency of SMBG tests without compromising glucose control

Jairia Dela Cruz, 2 days ago

Use of continuous glucose monitoring (CGM) in the management of diabetes may lead to performance of fewer self-monitoring blood glucose tests, without any deleterious impact on glycaemic control, according to a study presented at the 53rd Annual Meeting of the European Association for the Study of Diabetes (EASD 2017).

Low-energy diet helps maintain long-term weight loss in obese patients with knee osteoarthritis

2 days ago

The additional use of intermittent low-energy diet (LED) or daily meal replacements after a mean 10-percent weight loss and 1-year maintenance effectively maintains weight loss in obese patients with knee osteoarthritis for 3 years, according to a recent study.

Optimizing hormone replacement therapy in menopause

05 Apr 2017

At a recent lunch symposium held in conjunction with the 1st Malaysian Advances in Women’s Health Congress 2016, Professor Dr Jamiyah Hassan imparted clinical updates and strategies for the optimization of hormone replacement therapy in menopausal women. Highlights from her presentation are summarized below.

Novel Approaches in the Treatment of Dyslipidaemia and T2DM

16 Mar 2017

Recently, Dr Peter Lin of the Canadian Heart Research Centre spoke on treatment strategies in the management of dyslipidaemia and T2DM at an AstraZeneca-sponsored continuing medical education event. Highlights of his presentations are summarized below.

The Future of Osteoporosis Management

20 Jan 2017

At the recent Malaysian Osteoporosis Society 2016 Clinical Practice Guideline (CPG) Meeting held on the 8th of October 2016 at Ibis Styles Ipoh, Dr Hew Fen Lee and Professor Dr Chan Siew Pheng presented clinical guidance on the management of osteoporosis, and discussed whether the benefits of treatment outweigh the risks.

Role of gliclazide MR today: Efficacy and safety you can trust

04 Jan 2017

At the Diabetes Asia 2016 Conference organized by the National Diabetes Institute, Professor Jean Claude Mbanya presented the case for why gliclazide modified release (MR; Diamicron® MR, Servier) should be the treatment of choice for early and aggressive control of type 2 diabetes (T2D).

Preventing 3 key heart failure risk factors in midlife may prolong disease-free survival

Pearl Toh, 07 Dec 2016

Preventing hypertension, diabetes, and obesity, which are the major risk factors for heart failure (HF), by ages 45 and 55 years may lower risks of incident HF and prolong HF-free survival, suggests data from the Cardiovascular Disease Lifetime Risk Pooling Project.

VERTIS SU: Ertugliflozin noninferior to glimepiride in reducing HbA1c, at cost of genital infection

Pearl Toh, 20 Sep 2017

Semaglutide + standard of care encourages weight loss in patients with T2D and high CV risk

Roshini Claire Anthony, 19 Sep 2017

Nasal glucagon a desirable needle-free alternative for hypoglycaemia treatment in children

Jairia Dela Cruz, 19 Sep 2017

inTANDEM3 demonstrates potential of sotagliflozin in T1D

Roshini Claire Anthony, 18 Sep 2017

CGM adoption reduces frequency of SMBG tests without compromising glucose control

Jairia Dela Cruz, 18 Sep 2017

Increased meal frequency ameliorates glucose metabolism, satiety in obese patients with IGT, T2DM

Stephen Padilla, 18 Sep 2017

Increasing the frequency of meals (six-meal pattern), compared with a three-meal pattern, improves glucose metabolism and satiety in obese patients with impaired glucose tolerance (IGT) or type 2 diabetes mellitus (T2DM), according to a 24-week weight maintenance study presented at the 53rd Annual Meeting of the European Association for the Study of Diabetes (EASD 2017) in Lisbon, Portugal.